Evidence map›Paper›PMID 40417543›Full record

ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024

A Personalized Dosing Strategy Optimization for Diabetes Management: Applications to Gestational Diabetes Mellitus.

Eva K Lee, Xin Wei, Michael D Wright, Francine Baker-Witt

Abstract read
In one paragraph

Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eva K LeeCenter for Operations Research in Medicine and Healthcare, Atlanta, Georgia, USA.
Xin WeiGeorgia Institute of Technology, Atlanta, Georgia, USA.
Michael D WrightGrady Health System, Atlanta, Georgia, USA.
Francine Baker-WittEffingham Health System, Springfield, Georgia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type II diabetes mellitus is a disorder that disrupts the way the body uses glucose. It is managed by close monitoring of blood glucose levels while the clinician experiments with a dosing strategy based on some clinical guidelines and his/her own experience. In this study, we propose a treatment planning model that optimizes the dosing strategy for diabetes treatment. The model utilizes a patient's personalized characteristics of disease progression and dose-response to optimize the drug dosage. Such personalized evidence is estimated by a drug-dose-drug-effect predictive model using the daily blood glucose data recorded during the titration period. We apply these to a group of patients suffering from gestational diabetes. For each patient, drug-dose-drug-effect prediction was established based on the first four weeks of self-monitored blood glucose. The treatment model then individualizes and optimizes the dose regimen based on the patient's personalized drug-dose-drug-effect characteristics. Consistently, the optimized dose regimens use less amount of drug while achieving better glycemic control than the original regimens used to treat the patients. This results in the first mathematical model that is data-driven and evidence-based and that quantitatively optimizes dosage for the treatment of diabetes. The model can generate a personalized dose regimen that has a better treatment outcome and is more drug-efficient. Clinical trials must be conducted to gauge the overall effectiveness.

Indexed as

Diabetes, GestationalDiabetes Mellitus, Type 2Hypoglycemic AgentsInsulinPrecision MedicineBlood GlucoseDose-Response Relationship, DrugFemaleHumansPregnancyBlood GlucoseHypoglycemic AgentsInsulindiabetes managementdiabetes mellitusDose optimizationdrug-dose-drug-effect predictiongestational diabetes mellitusglycemic controlmulti-objective mixed integer programpersonalized medicinepersonalized treatment planningself-monitoring blood glucose

Identifiers

PMID40417543
PMCPMC12099437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.